Characteristics of 66 patients with IA–lymphoid neoplasms after pediatric ALL therapy
| Characteristic no (%) or median (IQR) . | Value . |
|---|---|
| Sex | |
| Male | 38 (58) |
| Female | 28 (42) |
| Genetic predisposition | |
| Down syndrome | 6 (9) |
| Unknown | 60 (91) |
| Underlying malignancy-lineage | |
| B-ALL | 51 (77) |
| T-ALL | 4 (6) |
| T-LBL∗ | 2 (3) |
| ALL with unspecified lineage | 9 (14) |
| Underlying malignancy-type | |
| Newly diagnosed | 62 (94) |
| Relapsed | 4 (6) |
| Age at ALL diagnosis | |
| Age < 10 y | 51 (77) |
| Age ≥10 y | 15 (23) |
| Median (IQR) | 4.5 (2.95-9.25) |
| Age at lymphoid neoplasm diagnosis | |
| Age <10 y | 45 (68) |
| Age ≥10 y | 21 (32) |
| Median (IQR) | 6.25 (4.5-12) |
| Lymphoid neoplasm: treatment era | |
| Before 1 January 2000 | 24 (36) |
| After 1 January 2000 | 42 (64) |
| Interval between leukemia and lymphoid neoplasm diagnoses (y) | |
| Median (IQR) | 1.89 (1.38-2.4) |
| Range | 0.35-4.06 |
| Time from maintenance initiation to lymphoid neoplasm diagnosis (mo) | |
| Median (IQR) | 14 (7-20.88) |
| Range | 0.5-96 |
| Timing of lymphoid neoplasm diagnosis | |
| During maintenance | 57 (86) |
| After maintenance completion | 9 (14) |
| Median (range); mo | 2 (0.25-6) |
| Maintenance regimen, no. (%) | |
| Mercaptopurine/methotrexate only | 34 (52) |
| Vincristine/corticosteroid pulses during maintenance | 26 (39) |
| Asparaginase/etoposide during maintenance | 3 (4.5) |
| Unknown | 3 (4.5) |
| Characteristic no (%) or median (IQR) . | Value . |
|---|---|
| Sex | |
| Male | 38 (58) |
| Female | 28 (42) |
| Genetic predisposition | |
| Down syndrome | 6 (9) |
| Unknown | 60 (91) |
| Underlying malignancy-lineage | |
| B-ALL | 51 (77) |
| T-ALL | 4 (6) |
| T-LBL∗ | 2 (3) |
| ALL with unspecified lineage | 9 (14) |
| Underlying malignancy-type | |
| Newly diagnosed | 62 (94) |
| Relapsed | 4 (6) |
| Age at ALL diagnosis | |
| Age < 10 y | 51 (77) |
| Age ≥10 y | 15 (23) |
| Median (IQR) | 4.5 (2.95-9.25) |
| Age at lymphoid neoplasm diagnosis | |
| Age <10 y | 45 (68) |
| Age ≥10 y | 21 (32) |
| Median (IQR) | 6.25 (4.5-12) |
| Lymphoid neoplasm: treatment era | |
| Before 1 January 2000 | 24 (36) |
| After 1 January 2000 | 42 (64) |
| Interval between leukemia and lymphoid neoplasm diagnoses (y) | |
| Median (IQR) | 1.89 (1.38-2.4) |
| Range | 0.35-4.06 |
| Time from maintenance initiation to lymphoid neoplasm diagnosis (mo) | |
| Median (IQR) | 14 (7-20.88) |
| Range | 0.5-96 |
| Timing of lymphoid neoplasm diagnosis | |
| During maintenance | 57 (86) |
| After maintenance completion | 9 (14) |
| Median (range); mo | 2 (0.25-6) |
| Maintenance regimen, no. (%) | |
| Mercaptopurine/methotrexate only | 34 (52) |
| Vincristine/corticosteroid pulses during maintenance | 26 (39) |
| Asparaginase/etoposide during maintenance | 3 (4.5) |
| Unknown | 3 (4.5) |
IQR, interquartile range; T-LBL, T-cell lymphoblastic lymphoma.
Two patients with T-LBL were treated with ALL therapy including methotrexate/thiopurine maintenance and developed LPDs during maintenance therapy. Histopathological specimens were reviewed by international experts and the 2 subsequent malignancies were determined to be molecularly and pathologically distinct.